Hookipa Pharma Inc

Price Chart

Risk-Adjusted Performance

Hookipa Pharma Inc (HOOK) Price Performance

Hookipa Pharma Inc (HOOK) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $1.10, down 3.51% from the previous close.

Over the past year, HOOK has traded between a low of $0.80 and a high of $1.75. The stock has gained 37.3% over this period. It is currently 37.0% below its 52-week high.

Hookipa Pharma Inc has a market capitalization of $13.06M.

About Hookipa Pharma Inc

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

Compare Hookipa Pharma Inc

Side-by-side comparison against top Healthcare peers.